Analysts who follow BridgeBio Pharma Inc (BBIO) on average expect it to gain 56.90% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns BBIO an Analyst Ranking of 73, which means it ranks higher than 73 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating BBIO a Strong Buy today. Find out what this means to you and get the rest of the rankings on BBIO!